CLAIM #6310 · Amgen Inc (AMGN) · 2025Q4 earnings call · Feb 3, 2026 · due Dec 31, 2026
“and we expect completion of the trials later this year, and we'll inform later about our plan to communicate this information.”
Jay Bradner · EVP R&D
PENDING
graded after results covering Dec 31, 2026 are reported
How to check this claim
Look at: Completion status of the referenced clinical trial(s)
It came true if: Company or clinicaltrials.gov reports trial(s) as completed (primary completion or full completion) by 2026-12-31
Where: Company press release, earnings call commentary, or clinicaltrials.gov trial status listing
Verify independently
SEC filings for AMGN ↗ · Claim quote is verbatim from the 2025Q4 earnings call.